Think long-term with this dermatology company.
News & Analysis: DermTech, Inc.
There are lots of reasons to be excited about DermTech's breakthrough diagnostic technology.
Swinging for the fences.
This high-flying healthcare stock should have more room to run.
Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years.
Shares of the skin-cancer genomics company gained as it opened up a new customer base.
Investor excitement mounted around the skin-care detection specialist.
The biotech's skin cancer diagnostic tool is a significant improvement over the standard of care.
The company's genomic test for melanoma won another positive coverage decision.
No news was good news.